405911-17-3 | 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$28.00	$19.00
5mg	95%	in stock	$44.00	$31.00
10mg	95%	in stock	$69.00	$48.00
25mg	95%	in stock	$106.00	$74.00
100mg	95%	in stock	$226.00	$158.00
250mg	95%	in stock	$373.00	$261.00
1g	95%	in stock	$933.00	$653.00

Description

• Catalog Number: AB74536
• Chemical Name: 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride
• CAS Number: 405911-17-3
• Molecular Formula: C33H32Cl2F3NO3
• Molecular Weight: 618.5133
• MDL Number: MFCD08276920
• SMILES: OC(=O)Cc1cccc(c1)OCCCN(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F.Cl

Computed Properties

• Complexity: 753
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 42
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 13

Literature

• B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals.

  Toxicology 20170701

• Cadmium-induced malignant transformation of rat liver cells: Potential key role and regulatory mechanism of altered apolipoprotein E expression in enhanced invasiveness.

  Toxicology 20170501

• Liver X receptor activation promotes differentiation of regulatory T cells.

  PloS one 20170101

• Influence of liver-X-receptor on tissue cholesterol, coenzyme Q and dolichol content.

  Molecular membrane biology 20121101

• Regulation of sphingomyelin phosphodiesterase acid-like 3A gene (SMPDL3A) by liver X receptors.

  Molecular pharmacology 20121001

• Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner.

  Antiviral research 20120901

• Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.

  Arteriosclerosis, thrombosis, and vascular biology 20120901

• Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin.

  Prostaglandins, leukotrienes, and essential fatty acids 20120701

• ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells.

  Biochemical and biophysical research communications 20120427

• Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells.

  Brain pathology (Zurich, Switzerland) 20120301

• Liver X receptor activation downregulates organic anion transporter 1 (OAT1) in the renal proximal tubule.

  American journal of physiology. Renal physiology 20120301

• Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism.

  PloS one 20120101

• Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20111102

• Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.

  The Journal of biological chemistry 20110923

• Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.

  The American journal of pathology 20110701

• LXR as a novel antithrombotic target.

  Blood 20110526

• Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4.

  Journal of immunology (Baltimore, Md. : 1950) 20110415

• Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.

  British journal of pharmacology 20110401

• Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.

  Journal of lipid research 20101201

• ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

  The Journal of biological chemistry 20101029

• Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100908

• Recent progress in liver X receptor-selective modulators.

  Current opinion in drug discovery & development 20100701

• The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.

  The Journal of biological chemistry 20100625

• X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling.

  Journal of molecular biology 20100528

• Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

  Journal of lipid research 20100401

• The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation.

  Journal of cellular physiology 20100401

• Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.

  Arteriosclerosis, thrombosis, and vascular biology 20100401

• Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.

  The Journal of biological chemistry 20100219

• Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.

  Shock (Augusta, Ga.) 20091101

• LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.

  Atherosclerosis 20091101

• Activation of liver X receptor regulates substrate oxidation in white adipocytes.

  Endocrinology 20090901

• The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro.

  Diabetologia 20090701

• Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.

  Cell metabolism 20081201

• Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.

  Journal of immunology (Baltimore, Md. : 1950) 20081115

• Treatment with LXR agonists after focal cerebral ischemia prevents brain damage.

  FEBS letters 20081015

• Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.

  Endocrinology 20081001

• Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.

  Circulation 20080930

• Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth.

  Journal of immunology (Baltimore, Md. : 1950) 20080915

• Androgen deprivation by activating the liver X receptor.

  Endocrinology 20080801

• PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine.

  Biochemical and biophysical research communications 20080711

• Ligand specificity and evolution of liver X receptors.

  The Journal of steroid biochemistry and molecular biology 20080501

• Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators.

  Journal of medicinal chemistry 20080410

• Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice.

  Arteriosclerosis, thrombosis, and vascular biology 20080301

• The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation.

  Atherosclerosis 20080101

• Liver X receptors (LXR) as therapeutic targets in dyslipidemia.

  Cardiovascular therapeutics 20080101

• Physiological differences between human and rat primary hepatocytes in response to liver X receptor activation by 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic acid hydrochloride (GW3965).

  Molecular pharmacology 20071001

• GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

  British journal of pharmacology 20070601

• Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists.

  Molecular human reproduction 20070601

• [Advances in the study of anti-atherosclerosis drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20070301

• Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2.

  Infection and immunity 20070201

• The nuclear receptor LXR is a glucose sensor.

  Nature 20070111

• Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.

  Circulation research 20060929

• Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study.

  Journal of lipid research 20060601

• A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors.

  The Journal of biological chemistry 20060224

• Oxysterols suppress inducible nitric oxide synthase expression in lipopolysaccharide-stimulated astrocytes through liver X receptor.

  Neuroreport 20060206

• Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation.

  Shock (Augusta, Ga.) 20060201

• Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.

  Circulation 20060103

• Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice.

  American journal of physiology. Endocrinology and metabolism 20051101

• Synthetic LXR agonists increase LDL in CETP species.

  Journal of lipid research 20051001

• Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.

  Circulation research 20041210

• Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.

  Journal of lipid research 20040801

• Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors.

  Assay and drug development technologies 20031201

• FXRE can function as an LXRE in the promoter of human ileal bile acid-binding protein (I-BABP) gene.

  FEBS letters 20031023